Online citations, reference lists, and bibliographies.

Improved Optimal Cytoreduction Rates For Stages IIIC And IV Epithelial Ovarian, Fallopian Tube, And Primary Peritoneal Cancer: A Change In Surgical Approach.

D. Chi, Corinna C D Franklin, D. Levine, F. Akselrod, P. Sabbatini, W. Jarnagin, R. DeMatteo, E. Poynor, N. Abu‐Rustum, R. Barakat
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To determine the impact of the incorporation of extensive upper abdominal debulking procedures on the rates of optimal primary cytoreduction and complications in stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal carcinomas. METHODS Two groups of patients were identified for comparison. Group 1, the control group, consisted of 70 consecutive patients who underwent "standard" primary cytoreductive surgery before May 2000. Group 2, the study group, was composed of 70 consecutive patients who underwent surgery after January 2001, during which time, a more comprehensive debulking of upper abdominal disease was used, including diaphragm stripping/resection, splenectomy, distal pancreatectomy, liver resection, resection of porta hepatis tumor, and cholecystectomy. RESULTS The median age of the entire cohort was 60 years (range, 36-88 years). The majority had stage IIIC disease (86%) and serous histology (76%). Optimal cytoreduction (residual disease
This paper references
10.3322/canjclin.53.1.5
Cancer Statistics, 2003
A. Jemal (2003)
10.1200/JCO.2003.02.153
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
R. Ozols (2003)
10.1006/gyno.1994.1346
Epithelial ovarian carcinoma: principles of primary surgery.
W. Hoskins (1994)
10.1097/00000658-200206000-00007
Quality of Complication Reporting in the Surgical Literature
R. Martin (2002)
10.1046/J.1525-1438.1998.09776.X
The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV
W. Kuhn (1998)
10.1006/GYNO.2001.6328
Identification of prognostic factors in advanced epithelial ovarian carcinoma.
D. Chi (2001)
10.1111/J.1048-891X.2004.014301.X
Predictive factors for irresectability in advanced ovarian cancer
H. Martínez-Said (2004)
10.1006/gyno.1996.4550
Stage IV ovarian cancer: impact of surgical debulking.
J. Curtin (1997)
10.1006/GYNO.2001.6312
What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
S. Eisenkop (2001)
10.1016/0002-9378(92)91345-B
The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer
P. Rose (1992)
10.1016/J.AJOG.2004.01.078
Morbidity of cytoreductive surgery in the elderly.
J. Wright (2004)
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
Griffiths Ct (1975)
10.1016/S0090-8258(03)00278-6
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.
S. Eisenkop (2003)
10.1006/GYNO.2000.5749
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
D. Chi (2000)
10.1200/JCO.1986.4.4.515
Prognostic factors in advanced ovarian carcinoma.
J. Redman (1986)
10.1006/GYNO.1998.4955
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
S. Eisenkop (1998)
10.1159/000076236
Can Optimal Primary Cytoreduction Be Predicted in Advanced Stage Epithelial Ovarian Cancer? Role of Preoperative Serum CA-125 Level
B. Obeidat (2004)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1016/S0002-9378(94)70090-7
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
W. Hoskins (1994)



This paper is referenced by
10.1016/S1636-5577(11)70720-9
Chirurgia dei tumori epiteliali maligni dell’ovaio
Philippe Morice (2011)
10.1016/B978-0-323-40067-1.00011-5
11 – Epithelial Ovarian Cancer
E. Eisenhauer (2018)
10.3892/IJO.30.3.727
Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma.
I. Skirnisdottir (2007)
10.1097/IGC.0000000000001180
Metastatic Involvement of Lesser Sac in Advanced Epithelial Ovarian Cancer
Asima Mukhopadhyay (2017)
10.1186/s12885-017-3311-8
Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma
S. Ye (2017)
10.1186/s12885-020-06886-2
Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial
S. Park (2020)
10.1016/J.YGYNO.2006.07.045
Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
G. Aletti (2007)
PARADIGM SHIFT IN THE MANAGEMENT OF GYNAECOLOGICAL CANCERS
Katelijn Sap (2015)
10.1016/j.ygyno.2008.10.008
Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
G. Aletti (2009)
What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?
P. Schwartz (2008)
10.1620/TJEM.218.5
Systematic lymphadenectomy improves survival in patients with advanced-stage primary fallopian tube cancer.
Yong Man Kim (2009)
10.1007/s10269-014-2403-1
La chirurgie des cancers de l’ovaire : les grands principes encore valides
F. Lécuru (2014)
Importancia de la temperatura de la quimioterapia intraperitoneal intraoperatoria con paclitaxel en el tratamiento quirúrgico radical de la carcinomatosis peritoneal de origen ovárico. Hipertermia versus normotermia
Ángela Casado Adam (2017)
10.1007/S11912-009-0062-Y
Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer
P. Schwartz (2009)
10.1097/IGC.0000000000000455
Postoperative Complications After Distal Pancreatectomy Performed During Cytoreductive Surgery for Gynecologic Malignancies
H. Mahdi (2015)
10.1097/IGC.0b013e3182013e2f
Neoadjuvant Chemotherapy Is Associated With Prolonged Primary Treatment Intervals in Patients With Advanced Epithelial Ovarian Cancer
M. R. Milam (2010)
10.1016/j.ygyno.2013.01.024
Advanced ovarian cancer: omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor.
F. Raspagliesi (2013)
Women's health and wellness
Nancy Liskar (2013)
10.1007/978-0-85729-910-9_1
Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer
Christina Fotopoulou (2014)
10.1016/J.JGYN.2014.07.015
Vers quelle chirurgie pour les cancers séreux avancés de l’ovaire ?
Fabrice Lécuru (2014)
10.1016/j.acra.2019.09.019
The Value of Contrast-Enhanced CT in the Detection of Residual Disease After Neo-Adjuvant Chemotherapy in Ovarian Cancer.
He An (2019)
10.1136/bcr-2017-221450
Relevance of enlarged cardiophrenic lymph nodes in determining prognosis of patients with advanced ovarian cancer
Hasan Shahriar Md Nuruzzaman (2018)
10.1016/J.COGC.2012.12.002
Improved 8-Year Survival for Patients With Stage IIIC Ovarian Cancer Operated on at Teaching Hospitals: Population-Based Study in Norway 2002
T. Paulsen (2012)
2. Surgical anatomy of upper abdominal solid organs for gynecologic oncologists
Y. Yildirim (2010)
10.1097/IGC.0b013e31824b403d
Does Significant Medical Comorbidity Negate the Benefit of Up-front Cytoreduction in Advanced Ovarian Cancer?
J. Ferriss (2012)
10.1016/J.AJOG.2005.06.074
Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients.
S. Sharma (2005)
10.1016/J.YGYNO.2006.03.051
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)
D. Chi (2006)
10.1007/s00404-016-4080-3
Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities
C. Fotopoulou (2016)
10.1007/S11912-007-0067-3
Operative management of primary epithelial ovarian cancer
M. Leitao (2007)
10.1007/978-0-387-98094-2_2
Staging and surgical treatment.
M. Leitao (2009)
Palliative Chirurgie des fortgeschrittenen Ovarialkarzinoms in der Ära der zielgerichteten Therapien
Georgios Papanikolaou (2015)
10.1002/cncr.22561
Centralization of care for patients with advanced‐stage ovarian cancer
R. Bristow (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar